Jon Edwards, Ph.D.

Dr. Edwards is Red Tree’s managing director and brings the firm broad life science company creation and investment experience. During his career, he has led and sourced more than 12 investments, with three of those taken public and three acquired, including the multi-billion dollar acquisitions of Synthorx, Inc. and Impact Biomedicines.

Prior to joining Red Tree, Dr. Edwards was on the founding team at Medicxi, a therapeutics-focused venture fund, where he was most recently a partner in Medicxi’s London office. He began his venture capital career at Index Ventures in Switzerland. Before moving to Europe, Dr. Edwards was a life sciences strategy consultant at ClearView Healthcare Partners based in Boston.

His investments previous include Synthorx (THOR; acquired by Sanofi), Phathom Pharmaceuticals (PHAT), Checkmate Pharmaceuticals (CMPI; acquired by Regeneron), Impact Biomedicines (acquired by Celgene), Sydnexis Inc., Xenikos B.V., and Breakpoint Therapeutics Gmbh. Dr. Edwards held board seats in all the aforementioned companies (observer seats in Synthorx and Checkmate Pharmaceuticals). He has also held board seats on Z-Factor Ltd., UltraHuman Ltd., and Palladio Biosciences and was a board observer with ApcinteX Ltd. and Capella Bioscience.

Dr. Edwards currently is a board member at Excellergy, Sardona Therapeutics, and Rondo Therapeutics. He received a Ph.D. in biochemistry and biophysics from the University of North Carolina at Chapel Hill and holds a B.S. from the University of Vermont. He began his career as a bench scientist at Sepracor, Inc. and conducted his postdoctoral research at MIT.